Sweden

OncoZenge

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

PHARMACEUTICAL MARKETING

Participation Not Confirmed

Update your events

OncoZenge Secures Approximately SEK 70 Million in Financing Ahead of spin-off and separate listing

Lead Product(s): Bupivacaine

Therapeutic Area: Neurology Product Name: BupiZenge

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Baltic Sea Foundation

Deal Size: $8.3 million Upfront Cash: Undisclosed

Deal Type: Financing November 16, 2020

Details:

OncoZenge is developing the BUPI project under the BupiZenge ® brand , for the treatment of pain due to oral mucositis, a serious side effect of cancer treatment. BupiZenge ® has shown promising results in a phase 2 study. The capital will be used to finance the phase 3 study.

IRLAB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

PHARMACEUTICAL MARKETING

Participation Not Confirmed

Update your events

IRLAB's Clinical Drug Candidate IRL752 Published in JPET

Lead Product(s): IRL752

Therapeutic Area: Neurology Product Name: IRL752

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 09, 2020

Details:

IRL752 is a drug candidate in clinical Phase II and is in development by IRLAB for the treatment of impaired balance (postural dysfunction) and falls in Parkinson's disease (PD-Falls).